Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by AIA Group Ltd

AIA Group Ltd increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 27.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,600 shares of the biopharmaceutical company's stock after purchasing an additional 2,959 shares during the quarter. AIA Group Ltd's holdings in Regeneron Pharmaceuticals were worth $9,688,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. Willner & Heller LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock valued at $284,000 after buying an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its holdings in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after acquiring an additional 15 shares during the period. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 18 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of research analysts recently weighed in on REGN shares. Bank of America restated an "underperform" rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $37.19 during trading on Friday, reaching $573.45. The company's stock had a trading volume of 1,547,645 shares, compared to its average volume of 686,669. The business's fifty day moving average price is $676.70 and its 200-day moving average price is $781.68. Regeneron Pharmaceuticals, Inc. has a twelve month low of $572.00 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market cap of $62.69 billion, a price-to-earnings ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.